M&A

M&A

Pharma major Lupin to acquire French firm Medisol for 18-M euros

BSE Disclosure  

Publicly listed pharma major Lupin Limited is to acquire the entire share capital of the French pharmaceutical company, Medisol for EUR 18 million (upfront EUR 14.5 million plus earn-outs up to EUR 3.5 million). The acquisition provides Lupin access to Medisol's portfolio of seven injectable products across four therapeutic areas: pain management, anti-inflammatory, cardiovascular diseases and obstetrics. Medisol, which was founded in 2011, specializes in generics injectables and is engaged in developing and commercializing its products, in pharmacies and hospitals in France. The company's revenues stood at EUR 7.3 million (estimated) in 2022.